Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
FDA GLP-1 Telehealth Marketing Warning Announcement In addition to Hims & Hers, these new set of warnings were sent to telehealth companies selling GLP-1 Weight Loss solutions, including: MaxLife, Measured, Zappy, Kin Meds, GoodGirlRx, WeightCare and PharmaZee among others
Pluvicto grew 42% at constant currencies in FY2024, becoming an increasingly significant revenue contributor as manufacturing capacity constraints that limited early sales have been progressively resolved
What pre-existing mental health changes: The threshold for noticing new symptoms is lower Existing symptoms can flare during any major medical change Coordination between the prescribing provider and any mental health provider becomes more important The patient and provider need to be more attentive to warning signs For patients in active treatment for anxiety or depression, the standard recommendation is to: Continue current psychiatric medications during tirzepatide titration Don't change psychiatric medications and start tirzepatide simultaneously Keep regular contact with the mental health provider Have a plan for worsening symptoms (when to call, what to do) Track mood as well as physical side effects during the first 12 weeks Most patients with stable, well-controlled mental health conditions do fine on tirzepatide
No comparable human dosing data exists for the BPC-157 and TB-500 combination, and these isolated findings do not establish safety for any combined use
